Skip to Content

Qiagen NV

QIA: XETR (DEU)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€73.00KznFxqwgykbz

Qiagen's Q1 Helped by Omicron Variant Surge; Shares Fairly Valued

No-moat Qiagen turned in strong results in the first quarter, helped by the omicron variant surge, and the company raised its guidance for 2022. However, we have not materially changed our underlying cash flow assumptions as our 2022 estimates were already in line with management's new outlook. We are maintaining our $48 fair value estimate for shares that trade in the U.S. and raising our fair value estimate for Qiagen shares on the German exchange to EUR 45 from EUR 42 previously as a result of recent currency exchange rate changes.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of QIA so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center